Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis

Oncogene

Volumn 34, Issue 14, 2014, Pages 1831-1842

  Zhou, J Z ^a   Riquelme, M A ^a   Gao, X ^a   Ellies, L G ^b   Sun, L Z ^a,c   Jiang, J X ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3'-O-(4-BENZOYL)BENZOYLADENOSINE 5'-TRIPHOSPHATE; ADENOSINE; ADENOSINE 5'-O-(3-THIOTRIPHOSPHATE); ADENOSINE A2A RECEPTOR; ADENOSINE TRIPHOSPHATE; ALENDRONIC ACID; APYRASE; BONE DENSITY CONSERVATION AGENT; PURINERGIC P2X RECEPTOR; SMALL INTERFERING RNA;

ANALOGS AND DERIVATIVES; ANIMAL; BONE TUMOR; BREAST TUMOR; C57BL MOUSE; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; OSTEOCYTE; PATHOLOGY; RNA INTERFERENCE; SECONDARY; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ADENOSINE; ADENOSINE TRIPHOSPHATE; ALENDRONATE; ANIMALS; APYRASE; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; OSTEOCYTES; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P2X; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84900359119     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.113     Document Type: Article

References (35)

1. Kohno N. Treatment of breast cancer with bone metastasis: bisphosphonate treatment-current and future. Int J Clin Oncol 2008; 13: 18-23.
2. Jin JK, Dayyani F, Gallick GE. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 2011; 128: 2545-2561.
3. Welch DR, Harms JF, Mastro AM, Gay CV, Donahue HJ. Breast cancer metastasis to bone: evolving models and research challenges. J Musculoskelet Neuronal Interact 2003; 3: 30-38.
4. Roodman GD. Mechanism of bone metastasis. New Engl J Med 2004; 350: 1655-1664.
5. van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Lowik C. Monitoring metastatic behavior of human tumor cells in mice with speciesspecific polymerase chain reaction: elevated expression of angiogenesis and bone resporption stimulators by breast cancer in bone metastases. J Bone Miner Res 2001; 16: 1077-1091.
6. Bonewald LF. Osteocytes as dynamic multifucntional cells. Ann NY Acad Sci 2007; 1116: 281-290.
7. Matsuo K. Cross-talk among bone cells. Curr Opin Nephrol Hypertens 2009; 18: 292-297.
8. Brown SA, Guise TA. Cancer-associated bone disease. Curr Osteopor Rep 2007; 5: 120-127.
9. Plotkin LI, Manolagas SC, Bellido T. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem 2002; 277: 8648-8657.
10. Genetos DC, Kephart CJ, Zhang Y, Yellowley CE, Donahue HJ. Oscillating fluid flow activation of gap junction hemichannels induces ATP release from MLO-Y4 osteocytes. J Cell Physiol 2007; 212: 207-214.
11. Shabbir M, Burnstock G. Purinergic receptor-mediated effects of adenosine 5?-triphosphate in urological malignant diseases. Int J Urol 2009; 16: 143-150.
12. White N, Burnstock G. P2 receptors and cancer. Trends Pharmacol Sci 2006; 27: 211-217.
13. Rapaport E, Fishman RF, Gercel C. Growth inhibition of human tumor cells in soft-agar cultures by treatment with low levels of adenosine 5?-triphosphate. Cancer Res 1983; 43: 4402-4406.
14. Salvestrini V, Zini R, Rossi L, Gulinelli S, Manfredini R, Bianchi E et al. Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. Blood 2012; 119: 217-226.
15. Rapaport E. Experimental cancer therapy in mice by adenine nucleotides. Eur J Cancer Clin Oncol 1988; 24: 1491-1497.
16. Deli T, Csernoch L. Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors. Pathol Oncol Res 2008; 14: 219-231.
17. Savariar EN, Felsen CN, Nashi N, Jiang T, Ellies LG, Steinbach P et al. Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res 2013; 73: 855-864.
18. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C et al. International Union of Pharmacology LVIII: update on the P2Y G proteincoupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 2006; 58: 281-341.
19. Batra N, Kar R, Jiang JX. Gap junctions and hemichannels in signal transmission, function and development of bone. Biochim Biophys Acta 2012; 1818: 1909-1918.
20. Burnstock G. Unresolved issues and controversites in purinergic signalling. J Physiol 2008; 586: 3307-3312.
21. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 2006; 103: 13132-13137.
22. Falzoni S, Donvito GD, Di Virgilio F. Detecting adenosine triphosphate in the pericellular space. Interface Focus 2013; 3: 20120101.
23. Leth-Larsen R, Lund R, Hansen HV, Laenkholm AV, Tarin D, Jensen ON et al. Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics 2009; 8: 1436-1449.
24. Zhi X, Chen S, Zhou P, Shao Z, Wang L, Ou Z et al. RNA interference of ecto-5?-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin Exp Metastasis 2007; 24: 439-448.
25. Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X et al. Ecto-5?-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 2008; 134: 365-372.
26. Jelassi B, Chantôme A, Alcaraz-Pérez F, Baroja-Mazo A, Cayuela ML, Pelegrin P et al. P2X(7) receptor activation enhances SK3 channels-and cystein cathepsindependent cancer cells invasiveness. Oncogene 2011; 30: 2108-2122.
27. Woodhouse EC, Amanatullah DF, Schetz JA, Liotta LA, Stracke ML, Clair T. Adenosine receptor mediates motility in human melanoma cells. Biochem Biophys Res Commun 1998; 246: 888-894.
28. Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Adenosine receptors and cancer. Biochim Biophys Acta 2011; 1808: 1400-1412.
29. Campbell JP, Merkel AR, Masood-Campbell SK, Elefteriou F, Sterling JA. Models of bone metastasis. J Vis Exp 2012; 67: e4260.
30. Kretschmann KL, Welm AL. Mouse models of breast cancer metastasis to bone. Cancer Metastasis Rev 2012; 31: 579-583.
31. Agteresch HJ, Dagnelie PC, Rietveld T, van den Berg JW, Danser AH, Wilson JH. Pharmacokinetics of intravenous ATP in cancer patients. Eur J Clin Pharmacol 2000; 56: 49-55.
32. Agteresch HJ, Burgers SA, van der GA, Wilson JH, Dagnelie PC. Randomized clinical trial of adenosine 5?-triphosphate on tumor growth and survival in advanced lung cancer patients. Anticancer Drugs 2003; 14: 639-644.
33. Beijer S, Hupperets PS, van den Borne BE, Eussen SR, van Henten AM, van den Beuken-van Everdingen M et al. Effect of adenosine 5?-triphosphate infusions on the nutritional status and survival of preterminal cancer patients. Anticancer Drugs 2009; 20: 625-633.
34. Zhang W, Tan S, Paintsil E, Dutschman GE, Gullen EA, Chu E et al. Analysis of deoxyribonucleotide pools in human cancer cell lines using a liquid chromatography coupled with tandem mass spectrometry technique. Biochem Pharmacol 2011; 82: 411-417.
35. Mishra S, Tang Y, Wang L, DeGraffenried L, Yeh IT, Werner S et al. Blockade of transforming growth factor-beta (TGFbeta) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line. Prostate 2011; 71: 1441-1454.